Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT<inf>1A</inf>Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats

Publication Type:
Journal Article
Citation:
Journal of Pharmacology and Experimental Therapeutics, 2004, 308 (3), pp. 1012 - 1020
Issue Date:
2004-03-01
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2012007895OK.pdf214.93 kB
Adobe PDF
The pharmacokinetic-pharmacodynamic (PK-PD) correlations of seven prototypical 5-HT1Aagonists were analyzed on the basis of a recently proposed semi-mechanistic PK-PD model for the effect on body temperature. The resulting concentration-effect relationships were subsequently analyzed on the basis of the operational model of agonism to estimate the operational affinity (pKA) and efficacy (log τ) at the 5-HT1Areceptor in vivo. The values obtained in this manner were compared with estimates of the affinity (pKi) and intrinsic efficacy (log[agonist ratio]) in a receptor-binding assay. Between 5-HT1Aagonists wide differences in in vivo affinity and efficacy were observed, with values of the pKAranging from 5.67 for flesinoxan to 8.63 for WAY-100,635 [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl) -N-2-pyridinyl-cyclohexanecarboxamide] and of the log τ ranging from -1.27 for WAY-100,135 [N-(1,1-dimethylethyl)-4-(2-methoxyphenyl)-α -phenyl-1-piperazine-propanamide] to 0.62 for R-(+)-8-hydroxy-2-[di-n-propylamino)tetralin. Poor correlations were observed between the in vivo receptor affinity (pKA) and the affinity estimates in the in vitro receptor binding assay (pKi; r2= 0.55, P > 0.05), which could in part be explained by differences in blood-brain distribution. In contrast, a highly significant correlation was observed between the efficacy parameters in vivo (log τ) and in vitro (log [agonist ratio]; r2= 0.76, P < 0.05). Thus by combining the previously proposed semi-mechanistic PK-PD model for the effect on body temperature with the operational model of agonism, a full mechanistic PK-PD model for 5-HT1Areceptor agonists has been obtained, which is highly predictive of the in vivo intdnsic efficacy.
Please use this identifier to cite or link to this item: